The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration

• Main Authors: Levine, Emily S. (Author), Custo Greig, Eugenia (Author), Mendonça, Luísa S. M. (Author), Gulati, Shilpa (Author), Despotovic, Ivana N. (Author), Alibhai, A. Yasin (Author), Moult, Eric Michael (Author), Muakkassa, Nora (Author), Quaranta-El Maftouhi, Maddalena (Author), El Maftouhi, Adil (Author), Chakravarthy, Usha (Author), Fujimoto, James G (Author), Baumal, Caroline R. (Author), Witkin, Andre J. (Author), Duker, Jay S. (Author), Hartnett, M. Elizabeth (Author), Waheed, Nadia K. (Author)
• Other Authors: Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor), Massachusetts Institute of Technology. Research Laboratory of Electronics (Contributor), Massachusetts Institute of Technology. Institute for Medical Engineering & Science (Contributor)
• Format: Article
• Language: English
• Published: Springer Science and Business Media LLC, 2020-12-23T20:24:56Z.
• Subjects: Article
• Online Access: Get fulltext

Background: The short-term effects of anti-vascular endothelial growth factor (anti-VEGF) treatment on macular neovascularization (MNV) morphology is well described, but long-term studies on morphologic changes and correlation of such changes to the type of MNV have not been conducted. This study aims to determine if different types of MNVs in neovascular AMD (nAMD) behave differently with anti-VEGF treatment as visualized on optical coherence tomography angiography (OCTA). Methods: Treatment-naïve nAMD patients were retrospectively screened for baseline and follow-up OCTA imaging 10 or more months after initial treatment. Images were graded for MNV type, area, activity, mature versus immature vessels, vessel density, presence of atrophy, atrophy location and area. Growth rate was calculated as the percent change in lesion area from baseline over the years of follow-up. In addition, the occurrence of complete regression and the percent of lesions that grew, remained stable, and shrunk per type was also evaluated. Results: Forty-three eyes from 43 patients with a mean follow-up of 2 years were evaluated. On structural OCT, 26 lesions were classified as pure type 1 MNVs, 12 MNVs had a type 2 component, and 5 MNVs had a type 3 component. Of these cases, 2 mixed-type MNVs were considered to have completely regressed. There was no significant differences in MNV area and growth rate between type 1 and type 2 lesions, but all cases of type 3 lesions shrunk in the follow-up period. There was no correlation between the number of injections per year and growth rate, endpoint MNV area or endpoint activity status for any MNV type. There was no significant association between the development of atrophy and the number of injections, baseline MNV area, baseline vessel density, or lesion growth rate. Conclusions: In nAMD, complete regression of an MNV network exposed to anti-VEGF is rare. This work emphasizes the role of anti-VEGF as anti-leakage rather than vascular regression agents in nAMD.
NIH (Grants R01EY015130, R01EY017011, EY014800 and R01EY011289)